Literature DB >> 22494774

Prognostic significance of tumor extension into venous system in patients undergoing surgical treatment for renal cell carcinoma with venous tumor thrombus.

H Miyake1, T Terakawa, J Furukawa, M Muramaki, M Fujisawa.   

Abstract

AIMS: The objective of this study was to evaluate the prognostic significance of the extent of a tumor thrombus in renal cell carcinoma (RCC) involving the venous system.
METHODS: This study included 135 consecutive RCC patients with a venous tumor thrombus undergoing radical nephrectomy and tumor thrombectomy between 1985 and 2009. These patients were classified based on the maximal level of the tumor thrombus extending into the venous system, as follows: group 1, renal vein; group 2, infradiaphragmatic; and group 3, supradiaphragmatic.
RESULTS: Of the 135 patients, 65, 49 and 21 were classified into groups 1, 2 and 3, respectively. The 1, 3 and 5-year cancer-specific survival (CSS) rates in these 135 patients were 89.2, 56.9 and 49.2%, respectively. Among several factors examined, tumor size, tumor grade, perirenal fat invasion and presence of metastasis, but not extent of tumor thrombus, were significantly associated with CSS on univariate analysis. Of these significant factors, only tumor size and presence of metastasis appeared to be independently related to CSS on multivariate analysis. When the patients without metastasis were analyzed separately, CSS in groups 2 and 3 was significantly poorer than that in group 1.
CONCLUSIONS: These findings suggest the absence of a significant prognostic impact of the level of the tumor thrombus in a complete cohort of RCC patients with a venous tumor thrombus; however, it is warranted to determine whether the level of the tumor thrombus has different effects on the prognosis according to the presence of metastatic diseases.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22494774     DOI: 10.1016/j.ejso.2012.03.006

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  2-[18F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma.

Authors:  Yanyan Zhao; Caixia Wu; Wei Li; Xueqi Chen; Ziao Li; Xuhe Liao; Yonggang Cui; Guangyu Zhao; Meng Liu; Zhanli Fu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-19       Impact factor: 9.236

2.  Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.

Authors:  Hideaki Miyake; Takayuki Sugiyama; Ryota Aki; Yuto Matsushita; Keita Tamura; Daisuke Motoyama; Toshiki Ito; Atsushi Otsuka
Journal:  Int J Clin Oncol       Date:  2018-01-13       Impact factor: 3.402

3.  Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center.

Authors:  Shingo Hatakeyama; Takahiro Yoneyama; Itsuto Hamano; Hiromi Murasawa; Takuma Narita; Masaaki Oikawa; Kazuhisa Hagiwara; Daisuke Noro; Toshikazu Tanaka; Yoshimi Tanaka; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama
Journal:  BMC Urol       Date:  2013-10-14       Impact factor: 2.264

4.  Clinical and oncological outcomes in Chinese patients with renal cell carcinoma and venous tumor thrombus extension: single-center experience.

Authors:  Xiaonan Chen; Shijie Li; Zhenqun Xu; Kefeng Wang; Donghui Fu; Qiang Liu; Xia Wang; Bin Wu
Journal:  World J Surg Oncol       Date:  2015-02-04       Impact factor: 2.754

5.  Surgical treatment for Xp11.2 translocation renal cell carcinoma with venous thrombus: A STROBE-compliant study.

Authors:  Liyuan Ge; Xiaojun Tian; Jing Ma; Guojiang Zhao; Yimeng Song; Shudong Zhang; Lulin Ma
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

6.  Pure laparoscopic radical nephrectomy and inferior vena caval tumor thrombus removal in patients with complicated renal tumor.

Authors:  Xin Zhang; Yan-Sheng Li; Bo Xiao; Tao Li; Peng Zhang; Yuan-Hao Chen; Xu-Hui Zhu; Xiu-Wu Han
Journal:  Chin Med J (Engl)       Date:  2019-10-05       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.